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Transcriptional dysregulation and aberrant chromatin remodeling are central features in the pathology of
Huntington’s disease (HD). In order to more fully characterize these pathogenic events, an assessment of his-
tone profiles and associated gene changes were performed in transgenic N171–82Q (82Q) and R6/2 HD mice.
Analyses revealed significant chromatin modification, resulting in reduced histone acetylation with concomi-
tant increased histone methylation, consistent with findings observed in HD patients. While there are no
known interventions that ameliorate or arrest HD progression, DNA/RNA-binding anthracyclines may provide
significant therapeutic potential by correcting pathological nucleosome changes and realigning transcrip-
tion. Two such anthracyclines, chromomycin and mithramycin, improved altered nucleosome homeostasis
in HD mice, normalizing the chromatin pattern. There was a significant shift in the balance between methyl-
ation and acetylation in treated HD mice to that found in wild-type mice, resulting in greater acetylation of
histone H3 at lysine 9 and promoting gene transcription. Gene expression profiling in anthracycline-treated
HD mice showed molecular changes that correlate with disease correction, such that a subset of downregu-
lated genes were upregulated with anthracycline treatment. Improved nucleosomal dynamics were concur-
rent with a significant improvement in the behavioral and neuropathological phenotype observed in HD
mice. These data show the ability of anthracycline compounds to rebalance epigenetic histone modification
and, as such, may provide the rationale for the design of human clinical trials in HD patients.
INTRODUCTION
Huntington’s disease (HD) is a fatal, autosomal dominant neu-
rodegenerative disorder of mid-life onset, characterized by
chorea, cognitive abnormalities and progressive dementia.
The behavioral symptoms of HD are the consequence of a
profound neurodegeneration, characterized by the primary
involvement of the basal ganglia with substantial neuronal
loss and concomitant astrogliosis (1). Underlying the beha-
vioral and neuropathological sequela observed in HD is a
genetic defect comprised of an expanded trinucleotide CAG
repeat within the coding region of the Huntingtin gene on
chromosome 4 (2). Normal huntingtin (Htt) is essential for
embryogenesis (3), and is believed to play a role in vesicular
transport (4). In addition, normal Htt may possess neuropro-
tective activity (5). In contrast, the trinucleotide expansion
in mutant Htt (mHtt), which is thought to confer both a
toxic gain-of-function in conjunction with a loss-of-function
(6), is the arbiter of the neurodegeneration observed in HD (7).
While steady advances have been made over many years,
the current understanding of disease pathogenesis has been
greatly enhanced by the development of transgenic murine
models of HD, which serve as valuable tools to study candi-
date disease mechanisms. The two most widely characterized
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HD mice are the N171–82Q (82Q) and R6/2 models (8,9).
Both 82Q and R6/2 mice display progressive HD-like beha-
vioral, biochemical and neuropathological alterations that par-
allel similar findings in HD patients (8–11). In addition,
significant alterations in transcriptional activity mediated by
mHtt have also been described in both 82Q and R6/2 mice
(12–15).
One mechanism by which mHtt impacts transcription is
through altered nucleosome dynamics. Important in this
context, histone methylation and acetylation status is closely
linked with transcriptional activity, regulating transcription
factor access to promoter regions in DNA (16,17). Histone
acetylation, which is generally regarded as promoting tran-
scription, is reduced in models of HD (18,19). Conversely,
histone methylation, which inhibits transcription, is increased
in both 82Q and R6/2 mice (19,20). Histone methylation is
also significantly elevated in HD patients (21). The disruption
of transcriptional homeostasis through altered methylation and
acetylation of histones and associated aberrant mHtt–protein
interactions may trigger signaling cascades associated with a
number of pathogenic mechanisms that can potentiate one
another. Once activated, these signaling cascades may ulti-
mately promote the neuronal dysfunction and subsequent
cell death observed in HD. Conversely, drug agents that can
realign chromatin homeostasis may improve HD-related defi-
cits in transcription and thereby improve disease phenotype.
To test this hypothesis, we administered chromomycin or
mithramycin to HD mice and assessed their ability to correct
aberrant nucleosomal dynamics and improve disease-related
changes in transcription.
RESULTS
In order to assess the effects of anthracycline administration
on nucleosome dynamics, western blot analyses of histone
methylation and acetylation status were performed on brain
samples from chromomycin-treated 82Q and R6/2 mice, as
well as mithramycin-treated 82Q mice. Anthracycline treat-
ment realigned chromatin homeostasis to that observed in
wild-type (WT) mice. Untreated 82Q mice had significant
hypoacetylation of H4, which was significantly improved by
chromomycin (Fig. 1A; F(2,18) ¼ 5.339; P , 0.02). Mithra-
mycin also significantly improved acetylation of histone H4
in 82Q mice [mean optical density (OD): WT, 0.436; 82Q
untreated, 0.360; 82Q mithramycin, 0.465; F(2,16) ¼ 4.965;
P , 0.02].
Concurrent analysis of methylation of histone H3 revealed
significant increases in tri-methylation of H3 in untreated 82Q
mice relative to WT controls (Fig. 1B; F(3,22) ¼ 4.507;
P , 0.02). Chromomycin significantly reduced tri-methylation
of H3 to levels indistinguishable from WT mice. Mithramycin
also significantly improved methylation (mean OD: WT,
0.158; 82Q untreated, 0.232; 82Q mithramycin, 0.141;
F(2,15) ¼ 29.755; P , 0.01). Similar results were observed in
R6/2 mice. Analysis of acetylation of histone H4 showed sig-
nificant hypoacetylation in R6/2 when compared with WT
mice. Chromomycin administration significantly restored
acetylation of histone H4 to WT levels (Fig. 1C;
F(3,22) ¼ 3.389; P , 0.05). There was also a significant
hypermethylation of histone H3 in untreated R6/2 mice when
compared with WT littermate control mice (Fig. 1D) that was
significantly reduced in chromomycin-treated R6/2 mice
[F(3,22) ¼ 7.059; P , 0.01]. In addition, chromomycin treat-
ment had no effect on total histone H3 levels in either 82Q or
R6/2 mice (82Q—F(2,15) ¼ 2.244; P . 0.05; R6/2—
F(2,15) ¼ 0.850; P . 0.05; data not shown).
As the methylation of histone H3 at lysine 9 is thought to be
a dominant marker of transcription repression and since
histone H3 can also be acetylated at lysine 9, the balance
between methylation and acetylation of histone H3 at lysine 9
is believed to play an important role in the transcriptional dis-
ruption observed in HD (21). The ratio of methylation versus
acetylation of histone H3 at lysine 9 in both 82Q and R6/2
mice showed significantly greater methylation when compared
with WT mice (Fig. 2A and B). In contrast, chromomycin in
82Q and R6/2 mice, and mithramycin in 82Q mice, signifi-
cantly shifted the tri-methyl/acetyl balance towards greater
acetylation of histone H3 at lysine 9 [F(2,15) ¼ 7.967;
P, 0.01; 82Q chromomycin: F(3,22) ¼ 2.925; P, 0.05; R6/2
chromomycin: F(2,15) ¼ 21.387; P , 0.01, 82Q mithramycin].
These findings demonstrate the ability of anthracyclines to
alter nucleosomal dynamics, through modification of histone
methylation and acetylation status, in a transcriptionally
proactive manner.
We next assessed the impact of the correction of aberrant
nucleosome status on mRNA levels in anthracycline-treated
animals. A comparison of untreated R6/2 and WT mice
showed a disease-related mRNA expression pattern in agree-
ment with previous studies (12), with significant alterations
observed in genes involved in neuronal signaling components,
such as enkephalin, BDNF and the dopamine D2 receptor.
Additional alterations in signal transduction, involving the
transcription factor CREB, as well as mitogen-activated
protein kinases, the cyclin-dependent kinase inhibitor 1A
(P21) and the regulatory subunit 1B of protein phosphatase
1 are observed. Changes are also observed in gene expression
involving products important to metabolism, such as
glycerol-3-phosphate dehydrogenase 1. Such expression
alterations correspond well with the metabolic dysfunction
and impaired synaptic function observed in R6/2 mice (22,23).
Consistent with the predicted improvement in transcrip-
tional status, mithramycin treatment ameliorated disease-
related changes in mRNA levels observed in R6/2 mice. The
main comparisons of interest are between mithramycin-
treated R6/2 and saline-treated wild type mice, and between
untreated R6/2 and wild type mice. In order to identify
genes responding to drug treatment in the HD mice, we first
restricted attention to genes differentially expressed between
HD and wild type in the saline condition using a stringent
threshold of B-stat . 0. We then identified which of these
genes appear to be similarly expressed between HD drug-
treated and wild type saline treated, using the criterion that
the B-stat for this comparison should be , 0, indicating a
drug-induced correction of a subset of aberrantly expressed
genes. This subset of genes where expression is corrected by
anthracycline treatment is represented graphically in the
lower right quadrant of Figure 2C. HD-related mRNA
changes were corrected by mithramycin treatment. While
anthracycline-induced mRNA changes were not observed in
Human Molecular Genetics, 2007, Vol. 16, No. 10 1165
genes such as CREB or BDNF, mRNA’s previously shown to
be altered in R6/2 mice and demonstrating mithramycin-
associated improvements in expression levels included the
regulatory subunit 1B of protein phosphate 1 and the Caþþ/
Calmodulin-dependent protein kinase I gamma, whose gene
products are involved in regulating calcium homeostasis and
signal transduction. A complete listing of mithramycin-
induced improvements in gene expression levels can be
found in Table 1.
Given the potential benefit on the overall HD phenotype
conferred by the anthracycline-mediated improvement in
nucleosomal dynamics, the effects of anthracycline
administration on behavior and neuropathology were
subsequently assessed in HD mice. Chromomycin signifi-
cantly extended survival in 82Q mice by 25.5% in comparison
with untreated mice (Fig. 3A; x2 ¼ 18.92; P , 0.0001; chro-
momycin: 168.1+ 3.3 days; untreated: 134.0+ 2.1 days).
Mithramycin (100 mg) administration, which has previously
been shown to be efficacious in R6/2 mice (20), also signifi-
cantly increased survival in 82Q mice by 21.0% (Fig. 3A;
x2 ¼ 24.02; P , 0.0001; mithramycin 161.9+ 3.6 days). In
addition, the most efficacious chromomycin dose (100 mg/kg)
significantly increased survival in R6/2 mice by 13.1%
(Fig. 3B; x2 ¼ 14.11; P , 0.001; chromomycin: 117.8+ 5.7
days; untreated: 104.2+ 1.9 days). Since there is evidence
to suggest that exceeding total cumulative dose of
Figure 1. Histone methylation and acetylation alterations in chromomycin-treated 82Q and R6/2 mice. (A) 82Q mice exhibit significant hypoacetylation of
histone H4 (AcH4) relative to WT mice at 120 days of age. Treatment with chromomycin (chromo) significantly improves acetylation of histone H4 in 82Q
relative to untreated mice. (B) In contrast, 82Q mice demonstrate significant hypermethylation of histone H3 at lysine 9 (tMH3-K9). Chromomycin adminis-
tration significantly improves methylation of histone H3 in 82Q mice. (C) R6/2 mice demonstrate significant hypoacetylation of histone H4 when compared
with WT mice at 90 days. Chromomycin administration significantly improves acetylation of histone H4 in R6/2 such that they are indistinguishable from
control mice. (D) R6/2 mice also exhibit a significant hypermethylation of histone H3 at lysine 9. Treatment with chromomycin significantly improves methyla-
tion of histone H3 in R6/2 mice. P, 0.05 versus untreated and chromo.
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mithramycin may result in toxicity, we introduced an
intermittent dosing schedule that parallels chronic dosing
in patients with HD. Interestingly, an intermittent mithramycin
dosing schedule (400 mg/dose/week) significantly extended
survival in R6/2 mice by 12.5% (R6/2 untreated, 104.5 days;
R6/2 intermittent mithramycin, 117.0 days; x2 ¼ 8.915;
P , 0.01).
While chromomycin and mithramycin significantly improve
survival in 82Q mice, there was no effect observed on overall
body weight loss (Fig. 3C). This was also true for R6/2 mice,
where no significant effect on overall body weight loss was
observed for chromomycin ,100 mg (Fig. 3D). However, in
mice receiving 200 mg of chromomycin, there was a signifi-
cant weight loss observed between 54 [F(4.60), 7.910:
P , 0.01] and 75 [F(4.60), 3.544; P , 0.01] days of age in
R6/2 mice, suggesting toxicity at this dose (Fig. 3D). These
findings are consistent with other compounds that remodel
chromatin and provide transcriptional homeostasis in murine
models of neurodegeneration (19–21).
An analysis of motor performance revealed significant
differences between chromomycin-treated R6/2, untreated
R6/2 and WT control mice in several measures of motor per-
formance beginning at five weeks of age. Total ambulatory
counts were significantly reduced in untreated R6/2 mice com-
pared with WT mice at 5 weeks of age [F(2,23), 10.478;
P , 0.0006] (Fig. 3E), and persisted through 14 weeks
[F(2,22), 27.652; P , 0.0001]. Chromomycin significantly
improved ambulation through 10 weeks [F(2,22), 6.876;
P , 0.0001]. A similar pattern was observed for distance tra-
veled (Fig. 3F). Untreated R6/2 mice traveled a significantly
shorter distance when compared with WT mice at 7 weeks
[F(2,23), 4.636; P , 0.02], through 14 weeks [F(2,22), 10.627;
P , 0.006]. Treatment with chromomycin significantly
increased distance traveled through 10 weeks [F(2,22), 8.391;
P , 0.01]. Changes in locomotion were accompanied
with an inverse pattern observed in resting time, where
untreated R6/2 mice rested significantly more than WT mice
beginning at 5 weeks of age [F(2,23), 4.452; P , 0.02]
(Fig. 3G), and persisting through 14 weeks [F(2,22), 34.102;
P , 0.0001]. Chromomycin treatment significantly reduced
R6/2 resting time through 10 weeks of age [F(2,23), 34.102;
P , 0.0001].
Anthracycline improvements in 82Q and R6/2 behavior
likely result from an overall improved neuronal status. Sup-
porting this view, chromomycin significantly abated the neu-
ropathological sequela found in 82Q and R6/2 mice. Gross
brain volume was significantly reduced in untreated 82Q
mice when compared with WT mice (Fig. 4A). Striatal neur-
onal area was also significantly reduced in untreated 82Q com-
pared with WT mice (Fig. 4B). Treatment with chromomycin
or mithramycin (100 mg/kg, respectively) significantly
improved gross brain volume in 82Q mice [Fig. 4C; F(4,33),
8.099; P , 0.001]. Anthracycline treatment also significantly
improved striatal neuronal area, where greater efficacy was
found in mithramycin-treated (67%) versus chromomycin-
treated (36%) 82Q mice [Fig. 4D; F(4,33), 161.23; P , 0.001].
As in the 82Q mice, there was also a significant reduction in
gross brain volume in untreated R6/2 mice when compared
with WT mice (Fig. 5A). In keeping with these findings,
there was a significant reduction in striatal neuronal area in
Figure 2. Histone H3 methylation versus acetylation balance in anthracycline
treated 82Q and R6/2, and effect on mRNA expression. (A) Examination of
the proportion of methylated H3 to acetylated H3 at lysine 9 (AcH3-K9)
reveals a significant shift toward greater methylation in 82Q mice relative to
WT control mice. In contrast, chromomycin (chromo) significantly shifts the
balance toward greater acetylation of H3 at lysine 9. (B) Further examination
of the relationship between methylated H3 and acetylated H3 at lysine 9
reveals a significant shift toward greater methylation in R6/2 mice relative
to WT controls. In contrast, chromomycin significantly shifts the balance
toward greater acetylation of H3 at lysine 9. (C) HD-related mRNA
changes show correction of a subset of genes by anthracycline treatment.
Plotted are individual gene B-statistics for the comparisons of mithramycin
(mith)-treated R6/2 animals compared with WT animals (Y-axis) versus
untreated R6/2 versus WT (X-axis). Dashed lines indicate the statistical
cut-off, B-stat thresholds of 0 for each comparison. The genes for which
expression is corrected toward WT by anthracycline treatment are indicated
in the lower right quadrant of the scatter plot. P, 0.05 versus untreated
and chromo.
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untreated R6/2 mice when compared with WT mice (Fig. 5B).
Chromomycin treatment (100 mg/kg) significantly improved
gross brain atrophy [Fig. 5C; F(2,10), 8.418; P , 0.01], and
the average striatal neuronal cell area in R6/2 mice [Fig. 5D;
F(2,10), 183.09; P , 0.001].
The improvements in overall neuropathology were coinci-
dent with an improvement in the levels of oxidative damage.
Urinary samples from 82Q mice showed significant elevations
in urinary 8-hydroxy 2-deoxyguanosine (8-OH2dG) in
untreated mice when compared with WT mice [Fig. 6A;
F(2,26) ¼ 5.417; P , 0.01]. There was a significant reduction
in urinary 8-OH2dG levels in chromomycin treated 82Q
mice when compared with untreated 82Q mice. Additional
analyses on brain 8-OH2dG levels revealed significant
anthracycline-mediated reductions. Brain 8-OH2dG levels
were elevated in both untreated 82Q and R6/2 mice
[F(3,32) ¼ 23.79; P , 0.01; F(2,19) ¼ 50.882; P , 0.01;
Fig. 6B and C, respectively]. Both human HD and R6/2
brain reveals significant oxidative DNA damage, demon-
strated by elevations in 8-OH2dG, associated with an impair-
ment of oxidative phosphorylation within the basal ganglia
(24,25). Chromomycin treatment in 82Q and R6/2 mice, and
mithramycin treatment in 82Q mice, significantly reduce
brain 8-OH2dG levels.
DISCUSSION
Chromatin structure in eukaryotic cells is a dynamic, yet
highly regulated process that occurs through interactions
between DNA and histone proteins. These interactions
influence efficient chromosomal packaging. Assemblies of
core histone proteins form an octamer around which DNA
can wind, resulting in distinct histone/DNA conformations:
condensed heterochromatin, with its compact nature tending
towards transcriptional silencing (26), or the more relaxed
euchromatin, a relatively open region of chromatin associated
with transcriptional activity (27). The associations of histone
proteins with DNA can be altered by epigenetic histone modi-
fications to influence transcription (16).
Among the more prominent modifications of histone
proteins H3 and H4, methylation and acetylation play a signifi-
cant role in transcriptional activity (16,17,26,28). Histone
acetylation is regulated through the concerted actions of
histone acetyltransferases (HAT) and histone deacetylases
(HDACs) (26). It is widely held that HAT activity results in
increased DNA transcription (29). In contrast, histone deacety-
lation mediated by HDAC activity, is associated with
transcriptional repression (27). Additional chromatin remodel-
ing is also mediated through the activity of histone
Table 1. Mithramycin treatment effects on gene expression in R6/2 cortex






1423854_a_at Ras-Like, family 11, member B Rasl11b 1.8921 20.8621 20.4517
1426980_s_at RIKEN cDDNA E130012A19 GENE E130012A19Rik 1.75474 20.8168 20.4310
1424986_s_at F-box and WD-40 domain protein 7, archipelago
homolog (drosophila)
Fbxw7 1.5460 20.5178 20.3372
1459903_at Semaphorin 7A Sema7a 1.4292 20.6536 20.4922
1419225_at Calcium chanel, voltage-dependent, alpha2/delta subunit 3 Cacna2d3 1.3726 20.6453 20.535
1448956_at START domain containing 10 Stard10 1.2238 20.3075 20.2490
1418744_s_at Tescalcin Tesc 1.2014 20.4808 20.4114
1425895_at_at Inhibitor of DNA binding 1 Idb1 1.1074 20.3951 20.1110
1421679_at_at Cyclin-dependent kinase inhibitor 1A (p21) Cdkn 1a 1.1067 20.5278 20.2343
1421992_atat Insulin-like growth factor binding protein 4 Igfbp4 1.1028 20.2935 20.2150
1421926_at Mitogen-activated protein kinase 11 Mapk 11 0.9429 20.3673 20.1711
1451331_at Protein phosphatase 1, regulatory (inhibitor) subunit 1B Ppp1r1b 0.9135 20.5214 20.1890
1417065_at Unknown – 0.8392 20.7233 20.5278
1424902_at Plexin domain containing 1 Pldc 1 0.7910 20.3604 20.2365
1423007_a_at Glial cell line derived neurotrophic factor family receptor alpha 2 Gfra2 0.6578 20.4378 20.2572
1424474_a_at Calcium/calmodulin-dependent protein kinase kinase 2, beta Camkk2 0.6487 20.7719 20.7079
1426562_at_at Olfactomedin 1 Olfm 1 0.6045 20.6501 20.5493
1424480_s_at Thymoma viral proto-oncogene 2 Akt2 0.5938 20.3678 20.2517
1417613_at Immediate early response 5 Ier 5 0.5535 20.7900 20.4980
1416192_at N-ethylmaleimide sensitive fusion protein attachment protein alpha Napa 0.4749 20.6227 20.5573
1420596_at Calcium channel, voltage-dependent, gamma subunit 2 Cacng2 0.3965 20.3963 20.1305
1423122_at Arginine vasopressin-induced 1 Avpi 1 0.3709 20.2772 20.207
1415973_at Myristoylated alanine-rich protein kinase C substrate Marcks 0.3513 20.2494 20.0257
1420008_s_at cDNA sequence BC07006 BC037006 0.3415 20.4294 20.2686
1421962_at Unknown – 0.2911 20.3328 20.2354
1423271_at Gap junction membrane channel protein beta 2 Gjb2 0.2360 20.2740 20.0756
1448249_at Glycerol-3-phosphate dehydrogenase 1 (soluble) Gpd 1 0.1603 20.3067 20.2655
1426614_at Protein kinase C binding protein 1 Prkcbp1 0.1334 20.6535 20.5285
1417071_s_at Cytochrome p450, family 4, subfamily v, polypeptide 3 Cyp4v3 0.1306 20.3433 20.2343
1424633_at Calcium/calmodulin-dependent protein kinase 1 gamma Camk1g 0.0122 20.2976 20.2640
mRNA differentially expressed between R6/2 and wild-type mice (both saline-treated) for which drug treatment of R6/2 mice corrects expression to be
more similar to wild-type, saline-treated mice.
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methytransferases, the actions of which may have profound
implications on transcriptional repression. Methylation of H3
at lysine 9, in particular, is thought to promote gene silencing
(30), although recent data suggests that the position of methyl-
ated histones along the entire gene can have an influence over
gene silencing versus transcription (31).
Changes in chromatin structure are a prominent pathologi-
cal feature of many neurodegenerative diseases. In Alzhei-
mer’s disease (AD), aberrant processing of the amyloid
precursor protein results in significant transcriptional altera-
tions (32,33). In keeping, altered gene transcription in AD
has recently been associated with alterations in histone
Figure 3. The effects of anthracycline administration on survival, body weight and locomotor behavior in 82Q and R6/2 mice. (A) 82Q mice received 100 mg/kg
of chromomycin (chromo, closed squares), 100 mg/kg mithramycin (mith, open diamonds) or 150 mg/kg mithramycin (open circles), in comparison with
untreated 82Q control mice (open triangles), all anthracycline treatments significantly extended survival in 82Q mice (100 mg/kg chromomycin, 25.4%;
100 mg/kg mithramycin, 21.0%; 150 mg/kg mithramycin, 10.3%). (B) R6/2 mice received either 15 (closed triangles), 50 (open squares), 100 (closed diamonds)
or 200 mg/kg (open diamonds) of chromomycin. Additional R6/2 mice were untreated (open triangles). Doses of 50 and 100 mg of chromomycin significantly
improved R6/2 survival by 5.8 and 13.1%, respectively. (C) 82Q mice treated with either 100 mg/kg chromomycin, 100 or 150 mg/kg mithramycin did not differ
in body weight from untreated 82Q mice at any time point examined. (D) R6/2 mice treated with 15, 50 or 100 mg/kg chromomycin demonstrated no significant
differences in body weight with WT mice at any time point examined. In contrast, R6/2 mice treated with 200 mg/kg chromomycin were significantly different
from all other groups between 54 and 68 days. (E) WT control mice (open circles) demonstrate significant elevations in total ambulatory counts, defined as the
total number of new beam breaks, over untreated R6/2 mice (closed squares). Chromomycin significantly improves total ambulatory counts in R6/2 mice (closed
circles). (F) Similar to above, R6/2 untreated mice demonstrate significant reductions in total distance traveled, with WT mice demonstrating significant
increases relative to untreated R6/2 mice. Chromomycin significantly improves R6/2 performance. (G) In contrast, R6/2 untreated mice demonstrate significant
increases in resting time compared to WT mice. Chromomycin significantly reduces R6/2 resting time. P, 0.01 versus Untreated; P, 0.05 versus Chromo;
#P, 0.01 versus Chromo; †P , 0.01 versus WT.
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acetylation profiles (34). Transcriptional anomalies are also
observed in Parkinson’s disease, where a subset of genes
identified in expression profiling studies are significantly dys-
regulated (35). In both cases, neuropathogenic alterations
in transcriptional activity lead to perturbations in normal
neuronal function and neuronal death. However, the associ-
ation between neuronal death and transcriptional dysfunction
is no more evident than in HD.
A profound aspect of disease pathology in HD is a signifi-
cant reduction in gene transcription (15,36,37). One molecular
basis for transcriptional dysregulation is likely to be the result
of direct interactions between the mHtt protein and several
transcription factors (38–41), which occur early in disease.
Interestingly, transcriptionally active anthracyclines and
HDAC inhibitors can improve transcription profiles in
murine models of HD (18–20). The mechanism by which
these compounds offer benefit is likely the result of epigenetic
modifications of the histone–DNA complex.
Experimental studies have linked significant hypoacetylation
of H4 in murine models of HD (18–20), and in human HD
(unpublished data). As well, hypermethylation of H3 is also
linked to human HD patients and HD mice (20,21). These epi-
genetic modifications of histone proteins in HD likely promote
alterations in chromatin packaging that results in transcriptional
Figure 4. Effects of anthracycline administration on 82Q brain morphology. (A) Gross brain volume is reduced in 82Q mice compared with WT control mice,
and a significant improvement is observed after either chromomycin (chromo) or mithramycin (mith) treatment. (B) 82Q mice also demonstrate a significant
decrease in striatal neuronal area when compare to WT control mice. (C) Chromomycin (100 mg/kg) and mithramycin (100 mg/kg) significantly improve
brain volume in 82Q mice. (D) Again, both chromomycin (100 mg/kg) and mithramycin (100 mg/kg) significantly improves average striatal neuronal area in
82Q mice compared to untreated mice. P, 0.01 versus WT-untreated; †P, 0.01 versus 82Q Chromo; # P, 0.01 v. 82Q Mith.
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repression. Compounds that can realign histone homeostasis
can exert neuroprotective effects. The anthracycline antibiotics
chromomycin and mithramycin are two clinically approved
DNA-binding drugs that are similar in structure and mechanism
of action. Chromomycin belongs to a class of aureolic acid
group antibiotics and is produced by Streptomyces griseus
(42). Mithramycin is produced by Streptomyces argillaceus.
The anti-tumor properties of mithramycin and chromomycin
Figure 5. Effects of anthracycline administration on R6/2 brain morphology. (A) Photomicrograph demonstrating the significant reduction in brain volume of
R6/2 when compared with WT control mice, with the improvement observed after chromomycin (chromo) treatment. (B) There is also a significant reduction in
striatal neuronal area in R6/2 when compared with WT mice, and the improvement after chromomycin administration (C) Chromomycin (100 mg/kg) signifi-
cantly improves brain volume in R6/2 mice. (D) In addition, chromomycin (100 mg/kg) significantly improves average striatal neuronal area in R6/2 mice.
P, 0.01 versus WT-untreated; †P , 0.01 versus R6/2 Chromo.
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are ascribed to their inhibitory effects on replication and the
transcription process. They act by selectively modulating
gene expression/transcription by displacing transcription acti-
vators and repressors that bind to guanine–cytosine-rich
regions of promoters (43–45). Anthracycline compounds
have also been demonstrated to interact directly with core
histone proteins H3 and H4 (46).
It may seem paradoxical that cytostatic or cytotoxic medi-
cations may have a role in neurodegenerative disorders.
While parallels between oncogenesis and neurodegenerative
disorders have been suggested, cellular stresses and transcrip-
tional signals elicit different responses in cells that enter the
cell cycle versus cells that are terminally differentiated,
leading to oncogenesis in the former, and neurodegeneration
in the latter. Stressed neurons respond transcriptionally by
turning genes on and off in compensation, with subsequent
triggering of genetic programs executing cell death. Compen-
satory genetic responses, as well as cell death, might also be
incompletely performed due to transcriptional dysregulation
(47). Thus, neurons may become even more vulnerable to
generic stress for which they cannot compensate and, at the
same time, may not be able to fully execute apoptosis. This
would explain why degenerating neurons (in humans and
transgenic mice) seem to persist for so long without expressing
a clear apoptotic phenotype.
Altered histone methylation and acetylation are consistent
with reduced transcriptional activity as related to the
‘histone code’ (30,48). Administration of chromomycin or
mithramycin significantly shifts the balance of methylation
versus acetylation of histone H3 at lysine 9 towards greater
acetylation. In turn, this promotes a transcriptionally proactive
chromatin packaging (29). As such, anthracyclines can
promote a return to neuronal homeostasis that results in sig-
nificant neuroprotection. Of principal importance, these thera-
peutic agents promote significant proactive changes in
nucleosomal dynamics that counteract the pathogenic disrup-
tions in transcriptional activity.
Both mithramycin and chromomycin have been used as
cancer chemotherapeutics. Mithramycin’s greatest use in
cancer was for testicular malignancy, although it is now
rarely used because of improved therapeutics for testicular
cancer. At lower doses, mithramycin is a very effective inhibitor
of osteoclastic activity, and has been used with good safety, tol-
erability and efficacy in Paget’s disease and hypocalcaemia of
malignancy until it was supplanted by biphosphates (43,49–
51). Interesting, mitoxantrone, another DNA-binding antibiotic
similar to mithramycin, has been effectively used in progressive
multiple sclerosis (52). While mithramycin and chromomycin
have not been used chronically and may have dose-related tox-
icity in humans (53), the present preclinical mouse studies
provide a rationale for the pursuit of safety and tolerability
trials using anthracycline compounds in HD patients.
MATERIALS AND METHODS
Animals
Transgenic male 82Q and R6/2 mice from stable established
colonies maintained at the Bedford facility were bred with
females from their background strain (B6 CBAFI/J). The
Figure 6. The effects of anthracycline administration on urinary and brain
8-OH2dG levels in 82Q and R6/2 mice. (A) Urinary 8-OH2dG levels are sig-
nificantly elevated in 82Q mice relative to WT mice. Chromomycin (chromo)
treatment significantly reduces 8-OH2dG levels in 82Q mice, indistinguishable
from WT mice. (B) A similar pattern is observed in brain 8-OH2dG levels.
Brain 8-OH2dG levels are significantly elevated in 82Q mice relative to WT
controls. Either chromomycin or mithramycin (mith) treatment significantly
reduces 8-OH2dG levels in 82Q mice, indistinguishable from WT mice.
(C) A similar pattern of significantly elevated brain 8-OH2dG is also observed
in R6/2 mice. Treatment with chromomycin significantly reduces 8-OH2dG
levels in R6/2 mice. P, 0.01 versus WT-untreated.
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progeny were genotyped via PCR assay on DNA isolated from
tail biopsy. The length of the CAG repeat was monitored by
the Core Sequencing Facility at Boston University. A total
of 90 transgenic female mice and 30 WT control female
mice were employed for experiments involving 82Q mice.
Experiments involving R6/2 mice required a total of 110 trans-
gene positive female mice and 30 littermate WT control
female mice. All mice of the same ‘F’ generation were
weighed at 20 days of age and equally distributed according
to parentage and weight within each group to ensure hom-
ogeneity of each experimental cohort. Mice under 8 g at this
time point were not used in the experiments. All mice were
housed five per cage under standard conditions with ad
libitum access to food and water. Enrichment conditions
were not applied to any cages. The mice were handled under
the same conditions by one investigator at the same time of
the day. All animal experiments were performed in accordance
with the NIH Guide for the Care and Use of Laboratory
Animals and were approved by both the Veterans Adminis-
tration and Boston University Animal Care Committees.
Drug administration
R6/2 mice (N¼ 10/group) received daily intraperitoneal (i.p.)
injection with chromomycin (vehicle, 15, 50, 100, 200, 400 and
600 mg/kg: SERVA Electrophoresis, Heidelberg, Germany) dis-
solved in normal saline (0.9%)/ethanol (0.0005%). 82Q mice
(N¼ 10/group) received daily i.p. injections of chromomycin
(vehicle, 100 mg/kg). Additional 82Q mice (N¼ 10) received
daily i.p. injections with mithramycin (100, 150 mg/kg; SERVA
Electrophoresis, Heidelberg, Germany) dissolved in normal
saline (0.9%). The initial dosing paradigm of 150 mg/kg mithra-
mycin in 82Q mice was chosen based on previous use of mithra-
mycin in R6/2 mice (20). However, this dose proved to be less
efficacious in extending survival, likely as a consequence of tox-
icity from prolonged administration of mithramycin. There is evi-
dence to support that mithramycin may result in cardiomyopathy
when the total cumulative dose is exceeded (53). All treatment
paradigms began at 28 days of age and included a group of
untreated WT. Injection volumes for all mice were 100 ml.
Animals used for microarray studies received 150 mg/kg/day of
mithramycin.
Microarray gene expression profiling
Total RNA of 10 mg from the cerebral cortices of individual
animals were processed using the Affymetrix GeneChip One-
Cycle Amplification kit and corresponding cRNA probes were
hybridized to MOE430A arrays. Quality of chip hybridization
images was assessed with the RMA-QC approach (54)
implemented in the BioConductor R package affyPLM. In
this method, gene expression is modeled as the sum of chip
and probe effects, with the model fit by robust regression
(i.e. outliers are downweighted). Pseudoimages of the robust
regression weights or residuals for each probe provide a
graphical means to assess chip quality; numerical measures
indicative of quality were also computed. By these criteria,
all chips were of similar and suitably high quality that none
required exclusion.
Survival
All mice were observed twice daily to monitor general feeding
capability and motor performance. Criteria for euthanasia was
the point in time when mice could no longer right themselves
after 30 s when positioned on their side and gently prodded.
This was confirmed by two separate observers (E.C.S. and
R.J.F.) and considered the time of death. A limited number
of deaths occurred overnight, and the time of death was
recorded as the following morning.
Motor performance and body weight
An Opto-Varimax Auto-Track System (Columbus Instru-
ments, Columbus, OH, USA) was used to assess motor per-
formance of R6/2 chromomycin-treated mice. Beginning
at 35 days of age, chromomycin-treated (100 mg/kg) and
-untreated transgenic mice (N ¼ 10/group) and WT (N ¼ 10)
mice were evaluated weekly on the same day and time.
Mice were placed in a clean, clear polycarbonate cage measur-
ing 29 cm  18.5 cm  12.5 cm. The cage was positioned
inside the horizontal sensor of the Opto-Varimax detector
array. The position of the cage in the array was kept constant
throughout testing. Any beam interruption is recorded and pro-
cessed by the Auto-Track System (ATS) software. The ATS
software recorded three separate measures: total ambulatory
counts, total resting time and total distance traveled. Body
weights were obtained once a week at the same day and time.
Histological evaluation
Chromomycin-treated (100 mg/kg) and -untreated 82Q
(N ¼ 10/group) and R6/2 (N ¼ 10/group), mithramycin-treated
(100 mg/kg) 82Q (N ¼ 10) mice, and WT (N ¼ 10) mice
were deeply anesthetized and transcardially perfused with 4%
buffered paraformaldehyde at 120 days of age for 82Q mice
and 90 days of age for R6/2 mice. The brains were removed,
post-fixed in the perfusate for 2 h, rinsed in buffer and cryopro-
tected in a graded series of 10 and 20% glycerol/2% dimethyl
sulfoxide. Frozen serial sections were cut at 50mm, stored in
6-well plates and stained for Nissl substance using cresyl
violet. Tissue sections were examined using a Nikon Eclipse
E800 microscope with a Spot RT digital camera.
Stereology and quantitation
Coronal-cut serial sections from the rostral segment of the
neostriatum to the level of the anterior commissure (interaural
5.34 mM/bregma 1.54 mM to interaural 3.7 mM/bregma
0.10 mM) (55) were used for all volumetric and striatal
neuron analyses. Striatal neuronal areas and striatal and ventri-
cular volumes were analyzed by microscopic video capture
and analyzed using ImageJ (56).
Western blot analysis
Brains from chromomycin-treated (100 mg/kg) and -untreated
82Q and R6/2 mice (N ¼ 10/group), mithramycin-treated
(100 mg/kg) and -untreated 82Q (N ¼ 10/group) and WT
(N ¼ 20) mice were processed for western blot analysis. The
82Q and R6/2 mice were euthanized at 120 and 90 days,
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respectively, and brains were flash frozen and stored at
2808C. Histone methylation and acetylation was determined
by western blot analysis as previously reported (18,20).
Frontal cortex was homogenized, processed for histone iso-
lation and total protein concentration was determined using
a DC assay kit (Bio-Rad, Hercules, CA, USA). Samples
were then subjected to SDS–PAGE (10%) and probed for
tMH3 (1:3000, Upstate, Charlottesville, VA, USA), AcH3
(1:1500; Upstate) or AcH4 (1:2000; Upstate). Protein
loading was controlled for by subsequently assessing
alpha-tubulin (1:5000; Upstate) on the same membrane.
Quantification of tMH3, AcH3, AcH4 and alpha-tubulin was
performed by densitometric analysis using NIH Image J (56).
High-performance liquid chromatography analysis
Urine samples were collected from 82Q mice (N ¼ 9/group) at
120 days of age and analyzed by HPLC for the detection of
free 8-OH2dG. Urine was collected in 1.5 ml tubes and
diluted 1:1 with 8% MeOH, 0.1 M lithium acetate, pH 6.4.
The dilution buffer dissolves particulates that co-precipitate
with 8-OH2dG. Samples were stored at 2808C. 8-OH2dG
was detected using a liquid chromatographic electrochemical
carbon column switching technique (57). Final 8-OH2dG con-
centration (ng/mg) was determined by the relative ratio of
8-OH2dG/creatinine. Brain samples from 82Q mice (N ¼ 9/
group) and R6/2 mice (N ¼ 7/group) were also analyzed for
the detection of 8-OH2dG (10). Samples were stored at
2808C. The supernatant of each sample (10 mL) was separ-
ated using the liquid chromatographic electrochemical
carbon column switching technique, as noted above. Standards
for 8-OH2dG were prepared in buffers used for sample prep-
aration, respectively, to accurately determine peak identity.
Statistics
Interval scale data involving only two independent groups
were analyzed using the t-test. Interval scale data involving
more than two groups were analyzed using one-way analysis
of variance. If an overall significant difference was detected,
multiple comparisons were performed with Fishers least sig-
nificant difference test. For all analyses, a significance level
of P  0.05 was observed. Statistical analyses of gene
expression measures were carried out with open source R soft-
ware packages available as part of the BioConductor project
(http://www.bioconductor.org). Gene expression was quanti-
fied by robust multi-array analysis (58,59) using the affy
package (60). To identify genes differentially expressed
between conditions for each brain region, we computed
single gene B-statistics (61) using the limma package (62).
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